Jagsonpal (JAGSNPHARM) | Stock Overview & Key Data
Jagsonpal Performance Comparison
Stock Range
Today's Range
Low: ₹220.55
High: ₹225.49
on October 3, 2025
52 Week Range
Low: ₹158.62
High: ₹328.04
on October 7, 2024
on November 29, 2024
All-Time High: ₹328.04 on November 25, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR15.1B
EPS
9.03
P/E Ratio (TTM)
24.59
Forward P/E
N/A
P/B Ratio
6.22
PEG Ratio
0.23
Div. Yield
1.01%
ROE
23.07%
Beta
0.153
Debt to Equity
3.85
Financial Highlights
Profitability
Gross Margin
64.39%
Operating Margin
15.69%
Profit Margin
21.50%
Returns and Earnings
Return on Assets (TTM)
19.90%
Return on Equity (TTM)
23.07%
EBITDA
INR645.2M
Net Income (TTM)
INR608.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR42.60
Quarterly Revenue Growth (YoY)
23.10%
Quarterly Earnings Growth (YoY)
102.60%
Dividend Information
Last 12-Month Dividend
₹2.50
Current Dividend Yield
1.01%
3-Year Average Dividend Yield
0.66%
3-Year Average Annual Dividend
₹1.37
3-Year Total Dividends
₹4.10
Ex-Dividend Date
September 12, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Jagsonpal JAGSNPHARM | 15.06B Small-cap | 2.97% | -10.86% | -3.68% | -5.22% | -14.79% | 26.76% | 48.31% | 1,160.48% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Innova Captab INNOVACAP | 48.64B Small-cap | 0.59% | -7.07% | -0.71% | -5.56% | -23.39% | 15.25% | 57.00% | 57.00% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Suven Life Sciences SUVEN | 47.99B Small-cap | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% | 46.77% | 186.97% | 307.88% |
Ownership & Short Interest
Insider Ownership
75.93%
Institutional Ownership
2.50%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
127K
Average 90-Day Volume
125K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JAGSNPHARM's 52-week high and low?
- In the last 52 weeks, Jagsonpal reached a high of ₹328.04 (on November 29, 2024) and a low of ₹158.62 (on October 7, 2024).
- What is the market cap and P/E ratio for JAGSNPHARM?
- Curious about Jagsonpal's size and valuation? Its market capitalization stands at 15.06B. When it comes to valuation, the P/E ratio (trailing twelve months) is 24.59, and the forward P/E (looking ahead) is N/A.
- Does JAGSNPHARM pay dividends? If so, what's the yield?
- Yes, Jagsonpal is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.01%, and the company has paid an average of ₹1.37 per share annually over the past 3 years.
- Who are Jagsonpal's main competitors or similar companies to consider before investing?
When looking at Jagsonpal, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Innova Captab
INNOVACAP48.64B Healthcare Drug Manufacturers - Specialty & Generic 15.25% 57.00% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Suven Life Sciences
SUVEN47.99B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Jagsonpal Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Jagsonpal's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 23.07%, the Debt to Equity ratio from the most recent quarter is 3.85, and its Gross Profit Margin stands at 64.39%.
- What is the recent revenue and earnings growth for JAGSNPHARM?
- Looking at Jagsonpal's growth, its revenue over the trailing twelve months (TTM) was INR3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 23.10%, and quarterly earnings saw a YoY growth of 102.60%.
- How much of JAGSNPHARM stock is held by insiders and institutions?
- Wondering who owns Jagsonpal stock? Company insiders (like executives and directors) hold about 75.93% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.50%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.